23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
23:54 , Jan 4, 2018 |  BC Extra  |  Company News

Management tracks: Acceleron, Selecta

Acceleron Pharma Inc. (NASDAQ:XLRN) said EVP and CMO Matthew Sherman will retire after the company reports top-line data mid-year from the Phase III MEDALIST and BELIEVE trials of luspatercept (ACE-536) to treat lower-risk myelodysplastic syndromes...
21:43 , Jan 3, 2018 |  BC Extra  |  Company News

Mendlein joins Moderna in strategy role

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) hired John Mendlein as president of corporate and product strategy. He will report to CEO Stéphane Bancel and will be responsible for corporate strategy; product advancement and strategy;...
17:36 , Nov 2, 2017 |  BC Extra  |  Company News

Management tracks: Melinta, Lundbeck

Infectious disease company Melinta Therapeutics Inc. (New Haven, Conn.) hired Dan Wechsler as president and CEO and John Bluth as EVP of investor relations and corporate communications. Wechsler was operating partner at Welsh, Carson, Anderson...
20:20 , Sep 8, 2017 |  BC Week In Review  |  Financial News

aTyr raises $45.8M

On Aug. 28, rare disease company aTyr Pharma Inc. (NASDAQ:LIFE) raised $45.8 million through two offerings. In a private placement, the company raised $15.6 million through the sale of 5.9 million shares at $2.65. The...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...
23:45 , Jul 19, 2017 |  BC Extra  |  Financial News

BIO calls for transparency in short selling

BIO supported measures to enhance transparency of short selling at a hearing Tuesday before the capital markets subcommittee of the House Committee on Financial Services. John Blake, SVP of finance at aTyr Pharma Inc. (NASDAQ:LIFE),...
01:21 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

Resolaris regulatory update

aTyr said FDA granted Fast Track designation to Resolaris to treat limb girdle muscular dystrophy 2B (LGMD2B). Resolaris, a protein therapy based on non-canonical functions of secreted forms of aminoacyl tRNA synthetases, has completed a...
17:18 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Resolaris: Interim ATYR1940-C-005 extension study data

Interim data from 4 evaluable adult patients with FSHD in the open-label, international ATYR1940-C-005 extension of the 12-week Phase Ib/II ATYR1940-C-002 trial showed that once-weekly 3 mg/kg IV Resolaris for ≥6 months led to no...
17:18 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Resolaris: Ph Ib/II ATYR1940-C-004 data

Top-line data from the open-label, placebo-controlled, intra-patient dose-escalation, international Phase Ib/II ATYR1940-C-004 trial in 18 patients with LGMD2B (n=10) or FSHD (n=8) showed that IV Resolaris improved muscle strength as measured by manual muscle testing...